Independent certification lab for AI in medical devices

Creating trust.

AI is now inside regulated medical devices — diagnosing, triaging, adapting — whether embedded in hardware or as software that is the device (SaMD). creiamo.ai verifies that the AI does what its technical file claims, and keeps proving it after the certificate issues. Independent, continuous, and on the record.

We find the gaps before your notified body does — then we keep watching.

Illustrative — demo data.
01

Probabilistic AI breaks deterministic conformity assessment.

Any company shipping AI inside a regulated device in Europe faces two costs. Getting the technical file through conformity assessment — typically 9 to 24 months, per Team-NB, the European association of notified bodies* — and most files arrive substantially incomplete. And proving the AI still behaves as certified once it's live — a post-market obligation regulators have made explicit for adaptive AI. We build the evidence layer for both.

Traditional compliance

Deterministic software

Same input, same output. Test once, sign off, ship. The assurance holds because the system cannot surprise you.

AI-enabled devices

Probabilistic systems

Novel outputs from identical inputs, and behaviour that evolves after deployment. The AI-specific evidence — robustness, drift, evaluation — is the newest part of the file, and the part reviewers question most.

every question round from your notified body costs months of queue — and the AI evidence is where the questions come from

* Team-NB, Medical Device Survey 2025 · team-nb.org

02

Find the deficiency letter before your notified body writes it.

A scoped 8–12 week engagement on one device, one regulatory route. Three steps, each leaving evidence you hold whether or not we ever work together again.

Certifica · the gap
By week 4

Gap assessment

Your technical documentation assessed against the AI-specific requirements inside the conformity procedure. Every finding named, versioned, and traceable — ready for your team to close.

Prova · under stress
Weeks 8–12

Submission-ready evidence

Robustness testing, drift characterisation, evaluation documentation — test protocols, results, and write-ups produced under stress and edge-case conditions, written into your risk management file and technical documentation, in your format.

Osserva · the trace
From day one

Live post-market stream

The device is instrumented during the engagement, so PMS, PMCF and PSUR inputs flow from the day the certificate issues — not retrofitted onto a certified device under change control.

Upstream, never in the way.Your notified body, consultants and submission timeline stay exactly as they are. We harden the file before it's assessed — we sit upstream of the review, never on your critical path.
Independent by design.We don't build clinical AI ourselves. And every result we report traces to a logged test, a versioned dataset and an audit record your reviewer can inspect. Say less. Prove more.

Work with us directly, or alongside the regulatory consultants you already trust — the evidence lands in your technical file, in your format, either way.

creiamo.ai is an independent laboratory for AI in medical devices. We are not a notified body and we issue no certificates — conformity assessment remains with your notified body. We produce the evidence it assesses.

Two ways to start.

Before you file

Certification readiness

For devices heading to CE marking or FDA clearance. A gap assessment of your technical documentation against the AI-specific requirements by week 4; submission-ready evidence — robustness testing, drift characterisation, evaluation documentation — written into your file, in your format, by week 12. Work with us directly or alongside your consultants. Your notified body and your timeline stay exactly as they are.

Already certified

Monitoring first

For devices on the market. We instrument the device and your PMS, PMCF and PSUR inputs flow from a live evidence stream — instead of being retrofitted onto a certified device under change control. As the device is updated or taken to new markets, the certification evidence stays current.

Either path can begin in the Founding Partners Program. Both leave evidence you hold.

Where we work.

We start where the obligation is statutory and the queue is longest: EU MDR and IVDR, with the AI Act requirements assessed inside the same conformity procedure. We also build FDA-facing evidence for US regulatory routes.

Filing somewhere else — the UK, Switzerland, or another market that recognises EU or US evidence? Tell us your route when you write. It won't change what you receive; it will shape what we prioritise next.

For regulatory consultants.

The AI sections of the technical file are the newest part of your clients' submissions — and the part a template can't produce. Robustness testing, drift characterisation, evaluation documentation: laboratory work, not paperwork.

Use creiamo.ai as the lab behind your practice. You keep the client, the file and the relationship; we produce the AI-specific evidence to your scope, in your client's format, under your review — and we never sit on your critical path. One client device is enough to start, on the same founding terms.

Request a scoping call — bring the device, we'll bring the evidence plan.

03

Medical devices first — deliberately.

The technology underneath — testing AI against its declared behaviour and generating regulator-grade evidence, continuously — isn't specific to medicine. It applies to any AI operating under a regulatory duty to prove itself. We start where the obligation is statutory, the assessment bottleneck is most acute, and the bar is highest: the hardest proving ground, and the beachhead for every regulated sector after it.

Now
Medical devices — hardware and software (SaMD) CE marking & FDA clearance · conformity evidence · post-market surveillance for adaptive AI
Then
The trust layer for the agentic economy Every sector where autonomous AI must prove itself — certification, continuous monitoring, and reliability ratings, on the record

The obligation to prove AI behaviour is spreading faster than the capacity to assess it. We build the evidence layer once — the regulated world reuses it.

04

Trust that is signed, dated, and accountable.

We never say "trust us." We show the evidence — every claim links to something verifiable.

We build

  • Certification evidence
  • Continuous monitoring
  • Reliability ratings

For

  • AI / SaMD manufacturers
  • Notified bodies & regulators
  • Insurers & investors

Across

  • Medical devices — now
  • Other regulated sectors — to come
Illustrative — demo data.

Frequently asked questions.

Is creiamo.ai a notified body?

No. creiamo.ai is an independent laboratory for AI in medical devices: we produce the evidence your notified body assesses — we do not issue certificates.

Does creiamo.ai cover software as a medical device (SaMD)?

Yes — hardware-embedded AI and SaMD, under EU MDR/IVDR with the AI Act requirements assessed in the same procedure, and FDA-facing routes.

Can regulatory consultants use creiamo.ai for their clients?

Yes. Consultants scope the evidence with us and keep the client, the file and the relationship.

Which markets does creiamo.ai work in?

The EU first (MDR/IVDR + AI Act); FDA-facing evidence for US routes; filing elsewhere, tell us your route.

Do notified bodies or authorities work with creiamo.ai?

Our evidence is built to be assessed: structured, versioned, and traceable to the test that produced it. If you review AI-enabled devices and want evidence in that form — or want to talk about reviewer-side tooling — write to us at hello@creiamo.ai.
Founding Partners Program · a small number, before we open widely

Hold the evidence before the review begins.

For companies with an AI-enabled device — physical or SaMD — heading toward — or already holding — CE marking or FDA clearance. Paid at a discounted founding fee, fully credited against the first-year service if you continue.

wk 4  gap assessment of your technical file
wk 12 submission-ready AI evidence, in your format
day 1  post-market monitoring live from certificate issue

Investor, or want to introduce a portfolio company? Same address — hello@creiamo.ai.

Regulatory route — tick all that apply
What happens next
1 · We reply within two business days.
2 · A 30-minute scoping call — both co-founders on it.
3 · A scoped proposal: one device, one route, fixed fee, milestone-split.

By submitting, you agree that we process these details to respond to your request — Privacy Notice (read online). You'll get a confirmation from hello@creiamo.ai. No newsletter, no resale.

Requested. Check your inbox — a confirmation is on its way from hello@creiamo.ai.

Sorry, something went wrong. Please try again, or write to hello@creiamo.ai.